Drug Profile
Research programme: humanised antibody therapeutics - CSL
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator CSL
- Developer Arana Therapeutics; CSL
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in Australia (Parenteral)
- 14 Apr 2010 Preclinical development is ongoing in Australia
- 24 Aug 2009 This programme is in active development